Loading news...
STE is buoyed by strong Healthcare and AST growth, solid margins and balance sheet strength, even as macro pressures and competition loom.
Benjamin Edwards Inc. lifted its position in STERIS plc (NYSE: STE) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,190 shares of the medical equipment provider's stock after acquiring an additional 2,741 shares during the quarter.
Gateway Investment Advisers LLC decreased its stake in STERIS plc (NYSE: STE) by 30.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,391 shares of the medical equipment provider's stock after selling 10,948 shares during the period. Gateway Investment
Shares of STERIS plc (NYSE: STE - Get Free Report) have earned an average rating of "Moderate Buy" from the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month target
Copeland Capital Management LLC cut its position in shares of STERIS plc (NYSE: STE) by 4.4% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 184,511 shares of the medical equipment provider's stock after selling 8,400 shares during the quarter. Copeland Capital Management
Carnegie Investment Counsel reduced its position in shares of STERIS plc (NYSE: STE) by 6.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 53,192 shares of the medical equipment provider's stock after selling 3,505 shares during the quarter. Carnegie Investment Counsel owned about 0.05% of
Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Addenda Capital Inc. acquired a new stake in STERIS plc (NYSE: STE) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,834 shares of the medical equipment provider's stock, valued at approximately $4,660,000. Other large investors also recently modified their
Sotera Health, a sterilization solutions provider, is gaining investor attention due to easing litigation and improving cash flow.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Axa S.A. raised its holdings in shares of STERIS plc (NYSE: STE) by 26.3% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,205 shares of the medical equipment provider's stock after acquiring an additional 7,320 shares during the quarter. Axa
Steris (STE) reported earnings 30 days ago. What's next for the stock?
STE posts solid AST and Healthcare growth, but currency swings and macro pressures pose rising challenges.
Groupe la Francaise boosted its position in shares of STERIS plc (NYSE: STE) by 19.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,527 shares of the medical equipment provider's stock after purchasing an additional 2,693 shares during the
STERIS (NYSE: STE - Get Free Report) and iRadimed (NASDAQ: IRMD - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a breakdown of recent ratings for
Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Total Revenue Growth: 10% as-reported revenue growth in Q2.Constant Currency Organic Revenue Growth: 9% in Q2.Gross Margin: Increased 60 basis points to 44.3%.
STERIS plc ( STE ) Q2 2026 Earnings Call November 6, 2025 9:00 AM EST Company Participants Julie Winter - Vice President of Investor Relations & Corporate Communications Karen Burton - Senior VP, CFO & Chief Accounting Officer Daniel Carestio - President, CEO & Director Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Patrick Wood - Morgan Stanley, Research Division Jason Bednar - Piper Sandler & Co., Research Division Michael Matson - Needham & Company, LLC, Research Division Michael Polark - Wolfe Research, LLC Presentation Operator Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today.
STERIS posts strong Q2 results with earnings and revenue beats, margin expansion, and a raised 2026 EPS outlook.